FGF23 and chronic kidney disease: In turn, the study by Isakova et al. [38] suggests that dietary phosphate restriction in combination with phosphate binder therapy may play a role in the diminishing of FGF23 levels in patients with CKD stages 3–4 and normal serum phosphate levels.